5Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs [ J ] . Journal of Biochemical & Molecular Toxicology, 1999, 13 ( 6 ) : 289-295.
6Nebot N, Crettol S, D' Esposito F, et al. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes [ J ] . BrJ Pharmacol, 2010, 161 ( 5 ) : 1059-1069.
8Gertz M, Tsamandouras N, S~ill C, et al. Reduced physiologically- based pharmacokinetic model of repaglinide : impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk [ J ] . Pharmaceutical Research, 2014, 31 ( 9 ) : 2367-2382.
9Khan MS, Barratt DT, Somogyi AA. Impact of CYP2C8"3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib [ J ] . Xenobiotica, 2016, 46 ( 3 ) : 278-287.
10Yu L, Shi D, Ma L, et al. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro [ J ] . Biopharmaceutics & Drug Disposition, 2013, 34 ( 5 ) : 278-287.
